The Impact of Androgen Deprivation Therapy on COVID-19 Illness in Men With Prostate Cancer.
Neil J ShahVaibhav G PatelXiaobo ZhongLuis PinaJessica E HawleyEmily LinBenjamin A GartrellVictor Adorno FeblesDavid R WiseQian QinGeorge S MellgardHimanshu N JoshiJones T NauseefDavid A GreenPanagiotis J VlachostergiosDaniel H KwonFranklin HuangBobby LiawScott T TagawaPhilip KantoffMichael J MorrisWilliam K OhPublished in: JNCI cancer spectrum (2022)
In this retrospective cohort of PCa patients, the use of ADT was not demonstrated to influence severe COVID-19 outcomes, as defined by hospitalization, supplemental oxygen use, or death. Age 70 years and older was statistically significantly associated with a higher risk of developing severe COVID-19 disease.
Keyphrases
- coronavirus disease
- sars cov
- prostate cancer
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- early onset
- middle aged
- respiratory syndrome coronavirus
- physical activity
- prognostic factors
- radical prostatectomy
- peritoneal dialysis
- stem cells
- bone marrow
- metabolic syndrome
- drug induced
- community dwelling
- patient reported